Prostate Cancer Health Center
Virus Linked to Prostate Cancer
Sept. 8, 2009 -- A virus may be responsible for some prostate cancers and hold clues to the cause of the deadly disease, according to a new study.
Xenotropic murine leukemia virus-related virus (XMRV) has been previously linked to leukemia and sarcomas in animals, but researchers say this has more recently been identified in human prostate cancer samples.
"We found that XMRV was present in 27% of prostate cancers we examined and that it was associated with more aggressive tumors," researcher Ila R. Singh, MD, PhD, associate professor of pathology at the University of Utah, says in a news release.
If further studies confirm that the virus causes prostate cancer, researchers say it would open new avenues for diagnostic tests, vaccines, and therapies for treating prostate cancer.
Prostate cancer affects one in six American men and is the most common type of cancer among men after skin cancer.
Clues to Prostate Cancer’s Cause
Previous studies have shown that a small group of men with a certain genetic variation were more susceptible to infection with XMRV, and the virus was present in about 10% of prostate cancer samples.
In this study, published in the Proceedings of the National Academy of Sciences, researchers examined about 200 cancerous prostate samples as well as 100 non-cancerous prostate samples.
They found 27% of the prostate cancers contained either XMRV DNA or proteins compared to 6% of healthy prostate cells. The virus was also more likely to be found in more aggressive prostate cancers.
In addition, the presence of XMRV was found in malignant prostate cancer cells, a finding that indicates the virus may be directly related to the formation of prostate cancer tumors or possibly that the virus has a preference to replicate within prostate cancer cells.
Finally, researchers say infection with XMRV was seen regardless of whether the men had the genetic variation making them susceptible to it, which would expand the “at-risk” population from a small group of genetically predisposed men to all men.
Viruses have previously been shown to cause other types of cancer, including cancer of the cervix and immune system ( lymphoma).
XMRV is a retrovirus that is known to cause cancer in animals but has not been proven to cause cancer in humans. However, researchers say these results show the virus merits further investigation as a potential cause of prostate cancer.
Indication
Uroxatral® (alfuzosin HCl 10 mg extended-release tablets) is an alpha1-blocker for the treatment of the signs and symptoms of BPH.
Important Safety Information
Do not take UROXATRAL if you have liver problems or if you are taking antifungal drugs like ketoconazole or itraconazole, or HIV drugs like ritonavir.
UROXATRAL can cause a sudden drop in blood pressure, especially when starting treatment. This may lead to fainting, dizziness, and lightheadedness. Do not drive, operate machinery, or do any dangerous activity until you know how UROXATRAL will affect you. This is especially important if you already have a problem with low blood pressure or take medicines to treat high blood pressure. There may be an increased risk of low blood pressure and fainting when taking UROXATRAL in combination with blood pressure medication or nitrates, or erectile dysfunction medication.
If considering cataract surgery (clouding of the eyes), tell your eye surgeon that you are currently taking UROXATRAL or have previously been treated with an alpha-blocker.
Before taking UROXATRAL, tell your doctor if you have kidney problems.
Also, tell your doctor if you or any family member(s) have or take medications for a rare heart condition known as congenital prolongation of the QT interval.
BPH and prostate cancer can cause the same symptoms. However, UROXATRAL is not a treatment for prostate cancer.
The most common side effects with UROXATRAL are dizziness, upper respiratory tract infection, headache, and tiredness.
Please see UROXATRAL full prescribing information.


